Literature DB >> 12404233

Restoration of acid secretion following treatment with proton pump inhibitors.

Jai Moo Shin1, George Sachs.   

Abstract

BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are covalent inhibitors of the gastric H+,K+-adenosine triphosphatase (ATPase) forming disulfide bonds. Recovery of acid secretion after PPI inhibition may be due to de novo synthesis of pump protein and/or disulfide reduction and reactivation of inhibited pump. The half-time of recovery of acid secretion in rats following omeprazole treatment is approximately 15 hours, whereas pump protein half-life is 54 hours. In humans, the half-life of the inhibitory effect on acid secretion is approximately 28 hours for omeprazole and approximately 46 hours for pantoprazole. Whereas all PPIs bind to cysteine 813, pantoprazole additionally binds to cysteine 822, deeper in the membrane domain of TM6. Their different durations of action may reflect different rates of pump reactivation due to differing accessibility of the disulfides to glutathione.
METHODS: Rats were stimulated and treated with 30 mg/kg of each PPI. Gastric ATPase was prepared and reversal of inhibition of the H+,K+-ATPase was measured as the time-dependent restoration of activity by incubation with dithiothreitol or glutathione.
RESULTS: One hundred percent reactivation of ATPase following inhibition in vivo by omeprazole or its enantiomers was seen with dithiothreitol and 89% with glutathione. Similar data were found for lansoprazole or rabeprazole. No reactivation by either reducing agent was seen following inhibition by pantoprazole.
CONCLUSIONS: Recovery of acid secretion following inhibition by all PPIs, other than pantoprazole, may depend on both protein turnover and reversal of the inhibitory disulfide bond. In contrast, recovery of acid secretion after pantoprazole may depend entirely on new protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404233     DOI: 10.1053/gast.2002.36593

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

Review 1.  Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.

Authors:  Aaron H Mendelson; Mark Donowitz
Journal:  Dig Dis Sci       Date:  2017-08-03       Impact factor: 3.199

2.  Suppression of contractile activity in the small intestine by indomethacin and omeprazole.

Authors:  Lenard M Lichtenberger; Deepa Bhattarai; Tri M Phan; Elizabeth J Dial; Karen Uray
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-02-26       Impact factor: 4.052

Review 3.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

4.  Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.

Authors:  Marinko Marusic; Zarko Babic; Mirjana Nesanovic; Mira Lucijanic-Mlinac; Vesna Stajcar
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 5.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

Review 6.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors.

Authors:  Artem Minalyan; Lilit Gabrielyan; David Scott; Jonathan Jacobs; Joseph R Pisegna
Journal:  Curr Gastroenterol Rep       Date:  2017-08

Review 8.  Pantoprazole: a proton pump inhibitor.

Authors:  Luis Moreira Dias
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 9.  The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.

Authors:  Alan B R Thomson
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  1-Arylsulfonyl-2-(pyridylmethylsulfinyl) benzimidazoles as new proton pump inhibitor prodrugs.

Authors:  Jai Moo Shin; George Sachs; Young-moon Cho; Michael Garst
Journal:  Molecules       Date:  2009-12-15       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.